List of Januvia drug patents
Januvia is owned by Merck Sharp Dohme.
Januvia contains Sitagliptin Phosphate.
Januvia has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Januvia are:
- US7125873
- US7125873*PED
- US6699871*PED
- US6699871
Januvia was authorised for market use on 16 October, 2006.
Januvia is available in tablet;oral dosage forms.
Januvia can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
The generics of Januvia are possible to be released after 24 May, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(8 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(8 months ago) | |
|
US7125873
(Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 months ago) | |
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(2 months ago) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering ...
Dosage: TABLET;ORAL
JANUVIA family patents
14
United States
5
Norway
5
Germany
5
European Union
3
Israel
3
Denmark
3
Austria
3
Argentina
3
Portugal
3
Spain
3
Korea, Republic of
3
Iceland
3
China
3
Georgia
3
EA
2
South Africa
2
Mexico
2
Australia
2
Hong Kong
2
Slovenia
2
Jordan
2
Hungary
2
Morocco
2
Costa Rica
2
Croatia
2
Brazil
2
Cyprus
2
Yugoslavia
2
Malaysia
2
Netherlands
2
Peru
2
Dominican Republic
2
Poland
2
Taiwan, Province of China
2
Ecuador
2
Luxembourg
2
Ukraine
2
Japan
2
Canada
2
New Zealand
2
ME
1
Lithuania
1
Belgium
1
Colombia
1
Bulgaria
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic